Blueprint Medicines (NASDAQ:BPMC) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their ...
House Republicans have taken a critical step to advance President Donald Trump’s tax cuts and border priorities through Congress, a major win for party leadership after quelling a conservative ...
Sanofi's deal to acquire Blueprint was announced on June 2nd ,for an initial amount of $9.1bn, or $129 per share. Sanoi will acquire Blueprint's approved drug for mastocytosis Aykavit, which earned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results